BiotechTube

Sitexsentin sodium + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diastolic Heart Failure

Conditions

Diastolic Heart Failure

Trial Timeline

Mar 27, 2006 → May 1, 2008

NCT ID
NCT00303498

About Sitexsentin sodium + Placebo

Sitexsentin sodium + Placebo is a phase 2 stage product being developed by Pfizer for Diastolic Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00303498. Target conditions include Diastolic Heart Failure.

What happened to similar drugs?

3 of 4 similar drugs in Diastolic Heart Failure were approved

Approved (3) Terminated (0) Active (1)
✅regadenosonAstellas PharmaApproved
✅ValsartanNovartisApproved
✅valsartanNovartisApproved
🔄Sildenafil + PlaceboPfizerPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00303498Phase 2Completed

Competing Products

6 competing products in Diastolic Heart Failure

See all competitors
ProductCompanyStageHype Score
regadenosonAstellas PharmaApproved
43
Dapagliflozin + PlaceboAstraZenecaPhase 2
31
ValsartanNovartisApproved
43
valsartanNovartisApproved
43
RanolazineGilead SciencesPhase 2
35
Sildenafil + PlaceboPfizerPhase 3
40